Laboratory Procedures. The Contractor agrees to restrict its laboratory provider network to entities having either a CLIA certificate of registration or a CLIA certificate of waiver.
Laboratory Procedures i. The laboratory utilized for blood and urine testing shall be designated by the County.
ii. Strict chain of custody procedures must be followed for all samples as set by NIDA. A split sample shall be reserved in all cases for an independent analysis in the event of a positive test result. All samples must be stored in a scientifically acceptable preservation manner as established by NIDA.
iii. All positive confirmed samples and related paperwork must be retained by the laboratory for at least one year or for the duration of any grievance, disciplinary action or legal proceedings regarding the sample, whichever is longer. At the conclusion of said period, the sample is to be destroyed along with laboratory maintained paperwork.
iv. The laboratory is authorized to test only for the following drugs or classes of drugs: marijuana metabolites, cocaine metabolites, opiate metabolites, Phencyclidine and amphetamines. The laboratory shall test only for these substances within the limits of initial and confirmation tests as currently defined by DHHS/SAMHSA. Initial testing will consist of a preliminary immunoassay (EMIT Screen). If initial testing results are negative, testing shall be discontinued.
v. Under this Agreement, the following cutoff levels shall be used in determining test results as positive or negative: Drug Class. Prelim. Cutoff Confirm. Cutoff Marijuana metabolites 100 ng/ml 15 ng/ml Cocaine metabolites 300 ng/ml 150 ng/ml Opiate metabolites Phencyclidine 2,000 ng/ml 25 ng/ml 2,000 ng/ml 25 ng/ml Amphetamines 1,000 ng/ml 500 /ml
vi. All initial and confirmatory testing shall be performed at a certified laboratory and not at any individual collection site.
vii. The laboratory will report to the MRO. Upon receipt of an initial positive test, the MRO shall investigate whether there are other alternative medical explanations. The MRO shall contact the Employee to request a valid prescription or other lawful authorization to use such substance, or to determine whether some other reasonable alternative medical explanation exists. Employees shall have 10 business days to submit such information to the MRO after being contacted. The MRO shall only report a positive result to the County in the case where both the preliminary and confirmatory test results are positive as to the same sample and the MRO's independent investigation provides no reasonable alternative medical explanation.
viii. In the event that tests are altered, invalid, diluted positive or po...
Laboratory Procedures. The laboratory utilized for blood and urine testing will be designated by the Employer after a recommendation of the OPBA prior to March 1, of each calendar year in which testing is to take place. The laboratory must have a current certification that it meets College of American Pathologists’ Forensic Drug Testing Accreditation standards as well as proof that it is operating with Department of Health and Human Services/Substance abuse and Mental Health Services Administration (SAMHSA) certification. Strict chain of custody procedures must be followed for all samples as set by NIDA. The Employer and the OPBA agree that security of submitted biological samples is such a paramount issue that any breach of the chain of custody or apparent tampering with sample integrity results immediately in an invalid sample that may not be used for any purposes. A split sample shall be reserved in all cases for an independent analysis in the event of a positive test result. All samples must be stored in a scientifically acceptable preservation manner as established by NIDA. All positive confirmed samples and related paperwork must be retained by the laboratory for at least one year or for the duration of any grievance, disciplinary action, or legal proceedings regarding the sample, whichever is longer. At the conclusion of said period, the sample is to be destroyed along with laboratory maintained paperwork. The laboratory is authorized to test only for the following drugs or classes of drugs: marijuana metabolites, cocaine metabolites, opiate metabolites, Phencyclidine, and amphetamines. The laboratory shall test only for these substances within the limits of initial and confirmation tests as currently defined by DHHS/SAMHSA. Initial testing will consist of a preliminary immunoassay (EMIT Screen). If initial testing results are negative, testing shall be discontinued. Under this Agreement, the following cutoff levels shall be used in determining test results as positive or negative:
Laboratory Procedures a. An employee of the testing laboratory shall remove the sealed plastic bag from the refrigerator at the collection facility, verify the integrity of the bag and transport the sealed plastic bag to the testing laboratory, where the date, time, name and signature of the receiving person is entered on the chain of custody record. Laboratories must comply with applicable provisions of any Federal and State licensing requirements. Accredited laboratories must have the facility and capability, onsite, of performing screening and confirmation tests for each drug or metabolite for which service is offered and requested. The testing laboratory shall maintain a chain of custody record of any individual handling or testing an Employee's specimen.
b. Lab Test:
i. The initial screening test will be of the RIA or EMIT type positive. If a result is obtained, a confirmation test will then be conducted.
ii. A confirmation or follow-up test will be of the Gas Chromatography/mass Spectrometry method and shall be conducted by the same laboratory which performed the initial screening. The laboratory shall be required to specify the metabolites tested for, the cut- off levels and the testing procedure used in each drug classification.
iii. In determining whether a test result is positive, the laboratory shall use the following cut- off levels: Initial Test Level Confirmatory Test Level
(1) Amphetamines 1000 ng/ml 500 ng/ml (2) Barbiturates 300 ng/ml 200 ng/ml (3) Cocaine Metabolite 300 ng/ml 150 ng/ml (4) Marijuana Metabolite 100 ng/ml 15 ng/ml
Laboratory Procedures a. Drug testing laboratories shall be secured at all times and shall have in place sufficient security measures to control access to the premises and to ensure that no unauthorized personnel handle the specimens or gain access to the laboratory process or have access to where records are stored.
b. Laboratories shall use chain of custody procedures to maintain control and accountability of specimens from receipt through completion of testing, reporting of results during storage, and continuing until final disposition of specimens. The date and purpose shall be documented on an appropriate Chain of Custody Form each time a specimen is handled or transferred and every individual in the chain shall be identi fied. Accordingly, authorized technicians shall be responsible for each urine specimen or aliquot in their possession and shall sign and complete Chain of Custody Forms for those specimens or aliquots as they are received.
(1) When a shipment of specimens is received, laboratory personnel shall inspect each package for evidence of possible tampering and compare information on specimen bottles within each package to the information on the accompanying Chain of Custody Forms. Any direct evidence of tampering or discrepancies in the information on specimen bottles and the Department's Chain of Custody Forms attached to the shipment shall be immediately reported to the Colonel and shall be noted on the laboratory's Chain of Custody Form which shall accompany the specimens while they are in the laboratory's possession.
(2) Specimen bottles generally shall be retained within the laboratory's accession area until all analyses have been completed. Aliquots and the laboratory's Chain of Custody Forms shall be used by laboratory personnel for conducting initial and confirmatory tests.
d. Specimens that do not receive an initial test within seven (7) days of arrival at the laboratory shall be placed in secure refrigeration units. Temperatures shall not exceed s ix (6) degrees Celsius. Emergency power equipment shall be available in case of prolonged power failure.
e. Laboratory facilities for urine drug testing will normally process specimens by grouping them into batches. When conducting either initial or con firmatory tests, every batch shall contain an appropriate number of standards for calibrating the instrumentation and a minimum of ten percent (10%) controls. Both quality control and blind performance test samples shall appear as ordinary samples to laborator...
Laboratory Procedures. Drug testing laboratories shall be secured at all times and shall have in place sufficient security measures to control access to the premises and to ensure that no unauthorized personnel handle the specimens or gain access to the laboratory process or have access to where records are stored. Laboratories shall use chain of custody procedures to maintain control and accountability of specimens from receipt through completion of testing, reporting of results during storage, and continuing until final disposition of specimens. The date and purpose shall be documented on an appropriate Chain of Custody Form each time a specimen is handled or transferred and every individual in the chain shall be identified. Accordingly, authorized technicians shall be responsible for each urine specimen or aliquot in their possession and shall sign and complete Chain of Custody Forms for those specimens or aliquots as they are received.
Laboratory Procedures. Every batch shall contain an appropriate number of standards for calibrating the instrumentation and a minimum of 10 percent controls. Both quality control and blind performance test samples shall appear as ordinary samples to laboratory analysis.
Laboratory Procedures. Upon sample custody transfer, the Contractor shall review the Chain of Custody (COC) or other approved form, to ensure that all information required for laboratory analytical services and data reporting has been recorded. If any information is missing from the COC, the Contractor shall attempt to notify the field crew responsible within forty-eight (48) hours to obtain the missing information. If the Contractor is not able to get the missing COC information within forty-eight (48) hours, the Contractor shall notify the Water Boards Project Manager and the Water Boards Contract Manager within three (3) business days.
Laboratory Procedures. Upon sample custody transfer, the SUB-LABORATORY shall review the Chain of Custody (COC) or other approved form, to ensure that all information required for laboratory analytical services and data reporting has been recorded. If any information is missing from the COC, the SUB- LABORATORY shall attempt to notify the PRIME LABORATORY’s project manager within forty- eight (48) hours to obtain the missing information. SUB-LABORATORY shall implement and document corrective actions when issues arise that impact the quality of the data. SUB-LABORATORY shall also respond to requests from PRIME LABORATORY for specific investigations, corrective actions, or verification of corrective action activities from SWRCB related to SUB-LABORATORY’s work. SUB-LABORATORY shall document and provide corrective actions in a Corrective and Preventive Action Report (CPAR) at the request of PRIME LABORATORY within twenty (20) business days of the request.
Laboratory Procedures for the analyses of aqueous and sediment toxicity of samples from freshwater estuarine and marine environments. County hereby engages Contractor to examine and perform toxicological analyses of aqueous and benthic sediment samples from freshwater, estuarine and marine environments by County. Contractor shall perform all analyses according to published methods presented in the following documents or their subsequent updates:
1. U.S. EPA. 1991a. Methods for Aquatic Toxicity Identification Evaluations: Phase I Toxicity Characterization Procedures, 2nd ed., EPA/600/6-91/003. U.S. Environmental Protection Agency, Office of Research and Development, Environmental Research Laboratory, Duluth, Minnesota.
2. U.S. EPA, 2002. Methods for Measuring the Acute Toxicity of Effluents and Receiving Waters to Freshwater and Marine Organisms, 5th Edition. EPA-821-R-02-012. U.S. Environmental Protection Agency, Office of Water, Washington, DC.
3. U.S. EPA. 1992. Toxicity Identification Evaluation: Characterization of Chronically Toxic Effluents, Phase I, EPA/600/6-91/005F. U.S. Environmental Protection Agency, Office of Research and Development, Environmental Research Laboratory, Duluth, Minnesota.
4. U.S. EPA. 1994 Methods for Assessing the Toxicity of Sediment-associated Contaminants with Estuarine and Marine Amphipods. EPA/600/R-94/025, U.S. Environmental Protection Agency, Office of Research and Development, Narragansett, Rhode Island.
